Oxford, UK, 24 September 2020 – Professor David Kerr, The Chief Medical Officer of Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today attended and presented remotely at the opening ceremony of BIO-FORUM 2020 (the 22nd Shanghai International Forum on Biotechnology and Pharmaceutical Industry) held at Pullman Shanghai South in China from 9th to 11th September.
The BIO-FORUM is a key platform on which the pharmaceutical and biotech industry participants, in close tie with academic scholars, regulators and other agencies discuss and exchange ideas, forge alliances, and promote collaborations across the industry and beyond. It is supported by the Ministry of Science and Technology of People’s Republic of China, Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Commission of Economy and Informatization, Shanghai Medical Product Administration, and other related organizations.
With the theme of “Strengthening the function of scientific and technological innovation source and leading the development of the biomedical industry”, BIO-FORUM 2020 focuses on industrial and social hotspots, reflecting Shanghai’s scientific and technological anti-epidemic achievements, and combining online live broadcasts, cloud exhibition halls and other forms to create BIO-FORUM 2020 Cloud Summit. The Conference invited well-known domestic and international scholars from the fields of biotechnology and medicine, corporate executives, as well as experts from government regulatory agencies, venture capital and other fields for in-depth discussions on cell therapy, development of new coronavirus treatment drugs and vaccines, biomedical innovation, biomedical engineering and other hot topics.
Professor David Kerr, Co-founder and Chief Medical Officer of Celleron Therapeutics, commented: “This forum brings together great minds about how our field and sector work together to translate fundamental scientific breakthroughs into effective novel medicines.”
NOTES:
About Celleron Therapeutics
Celleron Therapeutics is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies for different cancer indications. The company is a spin-out from Oxford University and located on the Oxford
Science Park, UK. Celleron Therapeutics has built a proprietary platform around epigenetic control and
immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron’s approach seeks
to align the right drug with the right patient enabling a personalised approach to cancer therapy.
Celleron Therapeutics’ focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines. Our goal is not only to treat cancer but improve quality of life during therapy by reduction of side effects.
Celleron has a global license partnership with Astra Zeneca and is also initiating new trials in China. The company secured investment in 2016 from a consortium of South Korean investors.